Literature DB >> 23321187

Comparative study of pelvic floor biofeedback training and tolterodine for treatment of detrusor after-contraction in posturination dribbling in children.

F Zeng1, H Q Chen, L Qi, X Y Zhang, Y Li.   

Abstract

OBJECTIVES: To investigate the prevalence of detrusor after-contraction (DA-C) in children with posturination dribbling, and compare the outcomes of pharmacological treatment and pelvic floor biofeedback training.
METHODS: Children with posturination dribbling underwent urodynamic studies. Patients with DA-C were randomly allocated to one of two groups: pelvic floor biofeedback training or 1 mg tolterodine, orally, twice daily. Treatment was continued for 12 weeks.
RESULTS: The study included 45 children. DA-C was present in 39 patients (86.6%), 30 (76.9%) of whom also exhibited detrusor overactivity. Pelvic floor biofeedback training resulted in a significantly better response than tolterodine, in terms of reduction in the number of posturination dribbling events in the month after completion of treatment.
CONCLUSIONS: DA-C is closely associated with posturination dribbling in children. Pelvic floor biofeedback training should be considered the initial treatment option in these patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23321187     DOI: 10.1177/030006051204000628

Source DB:  PubMed          Journal:  J Int Med Res        ISSN: 0300-0605            Impact factor:   1.671


  2 in total

1.  Can a four-session biofeedback regimen be used effectively for treating children with dysfunctional voiding?

Authors:  Nevzat Can Sener; Adem Altunkol; Umut Unal; Hakan Ercil; Okan Bas; Kemal Gumus; Halil Ciftci; Ercan Yeni
Journal:  Int Urol Nephrol       Date:  2014-09-14       Impact factor: 2.370

2.  Conservative interventions for treating functional daytime urinary incontinence in children.

Authors:  Brian S Buckley; Caroline D Sanders; Loukia Spineli; Qiaoling Deng; Joey Sw Kwong
Journal:  Cochrane Database Syst Rev       Date:  2019-09-18
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.